+150 XP

Why FMCG advertising claims get pulled after launch, not before

Kellogg's put "helps support your child's immunity" on Rice Krispies boxes in 2009. The cereal was in US grocery aisles nationwide before that sentence met anyone with enforcement power. In June 2010 the FTC (US Federal Trade Commission) expanded an existing order against the company so that it covered unsubstantiated health claims across Kellogg's foods. The FTC had obtained that order the previous year over Frosted Mini-Wheats advertising, which claimed the cereal improved children's attentiveness by nearly 20%. On the Mini-Wheats study, the FTC's position was that only about one in seven of the children tested had improved by that much.

Print runs, media flights and retailer promotions were all bought and committed before an outsider tested the evidence. That order of events is the norm in FMCG (fast-moving consumer goods: packaged food, drinks, cosmetics and household products sold in high volume). A claim launches, gets challenged, then gets pulled. The reverse almost never happens, and the reason is structural rather than sloppy.

The pre-clearance myth

Unlike prescription medicines, most FMCG advertising claims are not approved by any regulator before launch. There is no sign-off queue for "70% more moisturising" on a lotion bottle.

The system runs on ex-post enforcement: the advertiser self-certifies that a claim is substantiated, and regulators, competitors, plaintiff lawyers or watchdogs test that assertion afterwards. Each major market has its own version:

  • In the US, the FTC enforces Section 5 of the FTC Act, which bans "unfair or deceptive acts or practices".
  • In the EU, national consumer authorities apply the Unfair Commercial Practices Directive (2005/29/EC).
  • In the UK, the Advertising Standards Authority (ASA) takes tens of thousands of complaints a year and rules under the CAP Code, all of it after publication. Since April 2025 the CMA (Competition and Markets Authority) can also enforce consumer law directly.
  • In Australia, the ACCC (Australian Competition and Consumer Commission) litigates misleading conduct in the Federal Court.

So the check most marketers picture, a regulator reading copy before print, does not exist for everyday claims. The internal artwork and copy gates that a sibling lesson walks through catch spelling, allergens and legal wording. They do not verify that a study proves what the headline says. The real gatekeeper is the strength of your own evidence file.

Three claim types, three failure patterns

"Clinically proven." The phrase implies several things:

  • controlled trials
  • adequate sample size
  • statistical significance
  • testing on the finished product rather than one ingredient in isolation

The recurring failure mode is dose drift. The active is tested at a lab concentration well above what survives into the retail formula, and the retail formula inherits the claim.

Danone's Activia and DanActive marketing is the reference case. In December 2010 the FTC obtained a consent order barring the company from two claims without FDA (US Food and Drug Administration) approval: that Activia relieves temporary irregularity, and that DanActive prevents colds and flu. A roughly $21 million settlement with 39 state attorneys general came alongside it. Earlier that year, Danone had also withdrawn its Activia and Actimel health claim applications from EFSA (European Food Safety Authority) rather than see them rejected.

"Natural." No single legal definition exists in the US or EU for most categories, which makes the word more litigated, not less. US class actions (private suits brought on behalf of a group of consumers) have repeatedly targeted "all natural" on products containing synthetic preservatives or heavily processed ingredients.

In the EU, food claims run through the Nutrition and Health Claims Regulation (EC 1924/2006). Only claims on the EFSA register may be used, which is why "supports immunity" wording that circulates freely in one market is unusable in another.

Green wording now carries its own hard line. Since 27 September 2026, the EU's Empowering Consumers for the Green Transition Directive (EU 2024/825) blacklists two kinds of claim:

  • generic environmental claims such as "eco-friendly" or "green" unless the brand can show recognised excellent environmental performance
  • claims that a product is "climate neutral" or has a reduced impact because of carbon offsets

Packs printed before that date still have to comply once they are on sale.

"% more effective." Comparative claims mostly attract competitors, not regulators. Suppose Reckitt claimed a laundry treatment removed 50% more stains than the leading brand. The rival would not wait for the FTC. It has two routes:

  • file with the National Advertising Division (NAD), the self-regulatory body run by BBB National Programs
  • sue under the Lanham Act, which gives competitors standing on false advertising

In the EU, Directive 2006/114/EC requires comparisons to be objective, verifiable and not misleading.

Who actually pulls the claim

Four different actors do the pulling, at four different speeds.

  • Competitors move fastest, sometimes within weeks of launch. NAD decisions are not legally binding, but non-compliance gets referred to the FTC, and the industry treats a lost case as a shelf-life sentence on the claim. Most NAD cases end in modified wording rather than withdrawal, which is what a strong file buys you.
  • Regulators are slower and carry the penalty power.
  • The ASA cannot fine. Its sanctions are the published ruling with your brand named, removal of the ad, and referral to Trading Standards or the CMA.
  • The CMA is now a serious threat in its own right. Under the Digital Markets, Competition and Consumers Act 2024, it can decide a breach itself and fine up to 10% of global turnover without going to court first.
  • The ACCC goes to court, and the numbers get real. Reckitt sold its Nurofen Specific Pain range in Australia at a premium, with four variants each targeted at a different pain type and all using the same active ingredient. The Federal Court found the packaging misleading in 2015, and on appeal the penalty rose from A$1.7 million to A$6 million in December 2016.
  • EU authorities can reach up to 4% of annual turnover in the member states concerned for widespread infringements under the Omnibus Directive (EU 2019/2161).
  • Class action plaintiffs need no regulator at all. Red Bull settled US false advertising claims in 2014 with a fund of around $13 million, paying claimants roughly $10 in cash or $15 in product, while denying any wrongdoing. Note the boundary the case drew. "Gives you wings" reads as puffery. The surrounding energy, concentration and reaction-time messaging is measurable, and measurable is actionable.
  • Watchdogs and NGOs hold no legal power and set the media cycle anyway. Truth in Advertising (TINA.org) in the US and BEUC at EU level both feed complaints to regulators.

A claim can clear internal legal review and still die. Legal modelled regulatory risk, but nobody modelled the competitor whose brand manager has just lost two facings and has outside counsel on retainer.

What a substantiation file actually needs

Substantiation is the evidence you hold at the moment the claim is published, not evidence you assemble once challenged. Every forum above asks the same question: what did you have, and when. The US formulation is "competent and reliable scientific evidence". EU and UK frameworks phrase it differently and test the same thing.

A defensible file contains:

  1. Study design: sample size, control group, significance, run on the marketed formula and dose rather than a proxy.
  2. Claim-to-evidence mapping: the ad wording must match what was measured. "Reduces wrinkles" and "reduces the appearance of wrinkles" are different claims needing different proof.
  3. Comparative baseline documentation: for a "% more" claim, head-to-head testing against the competitor's current formulation, not last year's or their own marketing.
  4. Category sign-off, which depends on what you sell:
  • EU food and health claims: verification against the EFSA register
  • cosmetics: the EU Cosmetic Products Regulation (EC 1223/2009), which bans claims implying medicinal effects
  • environmental wording: a check against the EU 2024/825 blacklist
  1. Version control and an expiry date: substantiation decays. A supplier swap, a cost-down reformulation or a competitor reformulating their product can falsify a claim without a single word of copy changing.

Build the file as if a rival's outside counsel will read it in six months, because that is the realistic case.

Knowledge check

1. Why does the Kellogg's Rice Krispies example illustrate the typical FMCG claims pattern rather than an unusual failure?

2. What is the core structural reason FMCG brands can ship claims that later fail to hold up, despite having legal departments?

3. A marketer assumes that because a claim appeared in print, it must have passed some official regulatory review beforehand. What is the flaw in this assumption, based on the ex-post enforcement model?

MULTIPLE CHOICE

4. Select ALL correct answers about how regulatory enforcement of FMCG advertising claims works in the US, EU, and UK.

Select all the correct answers.

MULTIPLE CHOICE

5. Select ALL correct answers about why a phrase like 'clinically proven' carries specific risk for FMCG marketers.

Select all the correct answers.

When the claim gets pulled: what it actually costs

The withdrawal itself is rarely the expensive part. The costs sit downstream.

  • Packaging: artwork has to be re-originated and re-approved, and printed film and laminate for the old version becomes scrap.
  • Stock in the supply chain: stock already in the retailer's depot either gets stickered, which most grocers charge you for, or returned.
  • Media: media committed for the quarter is written off against a message you can no longer run.
  • The listing: this is the second-order problem. The claim was usually the reason the retailer took the listing. Pull it and the range review argument thins out, so the SKU competes on price at the next negotiation.

Two failure modes are worth naming.

The first is claim contagion. An FTC order, as Kellogg's found, can be written to cover a whole portfolio, not just the product that triggered it. Every future claim across the range then needs pre-approval that competitors do not need.

The second is asymmetric geography. A claim substantiated for the US can be unusable in the EU because it is absent from the EFSA register or falls foul of the green claims blacklist. A team that builds one global file discovers the gap after the pan-European launch, not before.

The FTC's guidance on health claims substantiation is a useful public reference even for teams working mainly in Europe, since the evidentiary logic carries across.

🎬 [VIDEO: "How the FTC Regulates Advertising" - https://www.youtube.com/results?search_query=how+the+ftc+regulates+advertising - search for FTC or law-school explainer videos covering Section 5 enforcement and substantiation standards, useful for a plain-language walkthrough of the ex-post enforcement model]

Key Takeaways

  • FMCG claims are almost never pre-cleared. Enforcement happens after the fact, so the safeguard is the evidence file you hold on the day of publication, not a government stamp.
  • "Clinically proven", "natural" and comparative "% more" claims fail in different ways:
  • dose drift between the tested and shipped formula
  • terms with no legal definition
  • comparators that have moved
  • In the EU, generic green claims and offset-based "neutral" claims are banned outright since 27 September 2026.
  • Competitors and class action plaintiffs often act faster than regulators, via NAD, the Lanham Act or a consumer suit, because their commercial motive is direct.
  • Penalties run from an ASA ruling with your brand named, through A$6 million against Reckitt in Australia, up to 4% of turnover under the EU Omnibus Directive and 10% of global turnover from the UK CMA.
  • The real cost of a pulled claim is downstream:
  • scrapped artwork and packaging
  • wasted media
  • retailer chargebacks
  • portfolio-wide orders
  • a listing that now has to be defended on price